|
1
|
Ayantunde AA and Parsons SL: Pattern and
prognostic factors in patients with malignant ascites: A
retrospective study. Ann Oncol. 18:945–949. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barni S, Cabiddu M, Ghilardi M and
Petrelli F: A novel perspective for an orphan problem: Old and new
drugs for the medical management of malignant ascites. Crit Rev
Oncol Hematol. 79:144–153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coupe NA, Cox K, Clark K, Boyer M and
Stockler M: Outcomes of permanent peritoneal ports for the
management of recurrent malignant ascites. J Palliat Med.
16:938–940. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Woopen H and Sehouli J: Current and future
options in the treatment of malignant ascites in ovarian cancer.
Anticancer Res. 29:3353–3359. 2009.PubMed/NCBI
|
|
5
|
Chung M and Kozuch P: Treatment of
malignant ascites. Curr Treat Options Oncol. 9:215–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Akgol G, Yildiz C, Karakus S, Koc M, Dogan
M, Turan M and Karadayi K: The effects of intraperitoneal
chemotherapeutic agents on adhesion formation. European J Gynaecol
Oncol. 37:781–785. 2016.
|
|
7
|
Cashin PH, Mahteme H, Graf W, Karlsson H,
Larsson R and Nygren P: Activity ex vivo of cytotoxic drugs in
patient samples of peritoneal carcinomatosis with special focus on
colorectal cancer. BMC Cancer. 13:4352013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Parson EN, Lentz S, Russell G, Shen P,
Levine EA and Stewart JH IV: Outcomes after cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy for peritoneal
surface dissemination from ovarian neoplasms. Am J Surg.
202:481–486. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guarneri V, Piacentini F, Barbieri E and
Conte PF: Achievements and unmet needs in the management of
advanced ovarian cancer. Gynecol Oncol. 117:152–158. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oh SY, Kwon HC, Lee S, Lee DM, Yoo HS, Kim
SH, Jang JS, Kim MC, Jeong JS and Kim HJ: A Phase II study of
oxaliplatin with low-dose leucovorin and bolus and continuous
infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer
patients with malignant ascites. Jpn J Clin Oncol. 37:930–935.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van der Speeten K, Stuart OA, Mahteme H
and Sugarbaker PH: Pharmacology of perioperative 5-fluorouracil. J
Surg Oncol. 102:730–735. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wyllie E and Wyllie R: Routine laboratory
monitoring for serious adverse effects of antiepileptic
medications: The controversy. Epilepsia. 32 Suppl 5:S74–S79.
1991.PubMed/NCBI
|
|
13
|
Jang JH, Kim MY, Lee JW, Kim SC and Cho
JH: Enhancement of the cancer targeting specificity of buforin IIb
by fusion with an anionic peptide via a matrix
metalloproteinases-cleavable linker. Peptides. 32:895–899. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lo A, Lin CT and Wu HC: Hepatocellular
carcinoma cell-specific peptide ligand for targeted drug delivery.
Mol Cancer Ther. 7:579–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiao W, Wang Y, Lau EY, Luo J, Yao N, Shi
C, Meza L, Tseng H, Maeda Y, Kumaresan P, et al: The use of
one-bead one-compound combinatorial library technology to discover
high-affinity αvβ3 integrin and cancer targeting
arginine-glycine-aspartic acid ligands with a built-in handle. Mol
Cancer Ther. 9:2714–2723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yao Z, Lu R, Jia J, Zhao P, Yang J, Zheng
M, Lu J, Jin M, Yang H and Gao W: The effect of tripeptide
tyroserleutide (YSL) on animal models of hepatocarcinoma. Peptides.
27:1167–1172. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawasaki M, Maeda T, Hanasawa K, Ohkubo I
and Tani T: Effect of His-Gly-Lys motif derived from domain 5 of
high molecular weight kininogen on suppression of cancer metastasis
both in vitro and in vivo. J Biol Chem. 278:49301–49307. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han X, Yan DM, Zhao XF, Matsuura H, Ding
WG, Li P, Jiang S, Du BR, Du PG and Zhu X: GHGKHKNK octapeptide
(P-5m) inhibits metastasis of HCCLM3 cell lines via regulation of
MMP-2 expression in in vitro and in vivo studies. Molecules.
17:1357–1372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamaguchi N and Kiick KL:
Polysaccharide-poly (ethylene glycol) star copolymer as a scaffold
for the production of bioactive hydrogels. Biomacromolecules.
6:1921–1930. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang J, Wang X and Lu H: Amifostine
increases cure rate of cisplatin on ascites hepatoma 22 via
selectively protecting renal thioredoxin reductase. Cancer Lett.
260:127–136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Santos FM, Latorre AO, Hueza IM, Sanches
DS, Lippi LL, Gardner DR and Spinosa HS: Increased antitumor
efficacy by the combined administration of swainsonine and
cisplatin in vivo. Phytomedicine. 18:1096–1101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghosh P, Sur P and Bag SP: Enhancement of
antitumor effects of a new boron compound combined with ultrasound
on the mouse ascites tumor. Med Chem. 8:1026–1031. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li C and Ren LQ: Replication of Animal
Models of Human Diseases. People's Medical Publishing House;
Beijing: pp. 612008, (In Chinese).
|
|
24
|
Su ZQ, Liu YH, Guo HZ, Sun CY, Xie JH, Li
YC, Chen JN, Lai XP, Su ZR and Chen HM: Effect-enhancing and
toxicity-reducing activity of usnic acid in ascitic tumor-bearing
mice treated with bleomycin. Int Immunopharmacol. 46:146–155. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ujioka T, Matsuura K, Tanaka N and Okamura
H: Involvement of ovarian kinin-kallikrein system in the
pathophysiology of ovarian hyperstimulation syndrome: Studies in a
rat model. Hum Reprod. 13:3009–3015. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morel G: Internalization and nuclear
localization of peptide hormones. Biochem Pharmacol. 47:63–76.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Finch AR, Caunt CJ, Armstrong SP and
McArdle CA: Agonist-induced internalization and downregulation of
gonadotropin-releasing hormone receptors. Am J Physiol Cell
Physiol. 297:C591–C600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim GD, Rhee GS, Chung HM, Chee KM and Kim
GJ: Cytotoxicity of 5-fluorouracil: Effect on endothelial
differentiation via cell cycle inhibition in mouse embryonic stem
cells. Toxicol In Vitro. 23:719–727. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen XX, Lai MD, Zhang YL and Huang Q:
Less cytotoxicity to combination therapy of 5-fluorouracil and
cisplatin than 5-fluorouracil alone in human colon cancer cell
lines. World J Gastroenterol. 8:841–846. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang SR, Hu GR, Fang LJ, Huang SJ, Li JS,
Zhao MY and Meng MJ: CpG oligodeoxynucleotides enhance
chemosensitivity of 5-fluorouracil in HepG2 human hepatoma cells
via downregulation of the antiapoptotic factors survivin and livin.
Cancer Cell Int. 13:1062013. View Article : Google Scholar : PubMed/NCBI
|
